Effects of an antithrombotic agent (MD-805) on progressing cerebral thrombosis
- 1 February 1989
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 53 (3) , 305-317
- https://doi.org/10.1016/0049-3848(89)90105-9
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulationCritical Care Medicine, 1984
- Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl]-2-piperidinecarboxylic acidBiochemistry, 1984
- Heparin therapy for strokeNeurology, 1984
- Antithrombin III deficiency in ischaemic strokeJournal of Molecular Medicine, 1983
- Heparin for lacunar stroke in progression.Stroke, 1983
- The timecourse of antithrombin III (AT III) level in the ischemic cerebrovascular diseaseJapanese Journal of Stroke, 1983
- Comparative study on heparin and a synthetic thrombin inhibitor no.805 (MD-805) in experimental antithrombin III-deficient animalsThrombosis Research, 1981
- Treatment of progressing stroke.Stroke, 1981
- A pilot study of urokinase therapy in cerebral infarction.Stroke, 1976
- Anticoagulant therapy in cerebral infarctionNeurology, 1962